[1]. Kim MC, Kini AS, Fuster V, Alexander RW, O’Rourke RA Definitions of Acute Coronary Syndroms. Hurst’s the
heart. 11th ed. USA: Mc Grow-Hill Companies 2004; 1215-49.
[2]. Haldong w,Amanuel A, Kalkim H, Cristiana A, Kaja MA, Foad Abd A,et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1084-1150.
[3]. Schoenenberger AW, Radovanovic D, Windecker S, Iglesias JF, Pedrazzini G, Stuck AE, Erne P, AMIS Plus Investigators, Lessing P, Hess F, Simon R. Temporal trends in the treatment and outcomes of elderly patients with acute coronary syndrome. European heart journal 2016; 12; 37(16): 1304-11.
[4]. Tofighiyan T, Rad M, Taghizadeh A, Rakhshani MH; Prevalence of Cardiac Arrhythmia Disorders in Patients with Myocardial Infarction Admitted to CCU Ward in the Vasei Hospital of Sabzevar. Jundishapur. J Chronic Dis Care 2012; 1(2): 38-44. (persian)
[5]. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrié D. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. The Lancet. 2016 Oct 22; 388(10055):2015-22.
[6]. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Journal of thrombosis and
thrombolysi2016 Jan 1; 41(1): 165-86.
[7]. Gavura S, Bayliff CD, Kovacs MJ. Evaluation of a Heparin Nomogram in the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. The Canadian Journal of Hospital Pharmacy 2018 May 15; 50(3).
[8]. Adib A, Fatorchi B. Comparative Study of Continuous and Intermittent Administration of Heparin on APTT
(Activated Partial Thromboplastin Time). Journal of Iran University of Medical Sciences 2005; 46(12): 243-48. (Persian)
[9]. Yadolahi E,Beigi A. Comparison of the efficacy of heparin injection in two continuous infusion methods and multiple intravenous infusion, on coagulation status after vascular surgery. Journal of Isfahan Medical School 2010;
150(29): 1046-51. (Persian)
[10]. Poortaghi S, Baghernia A, Golzari SE, Safayian A, Atri SB. The effect of home-based cardiac rehabilitation program
on self efficacy of patients referred to cardiac rehabilitation center. BMC research notes 2013; 6(1): 287.
[11]. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C,
Andò G, Repetto A. Bivalirudin or unfractionated heparin in acute coronary syndromes. New England Journal of Medicine 2015; 373(11): 997-1009.
[12]. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014; 64(24): e139-228.
[13]. Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, Steffenino G, Bonechi F, Mossuti E, Manari A, Tolaro S. Early aggressive versus initially conservative treatment in elderly patients with non–STsegment elevation acute coronary syndrome: a randomized controlled trial. JACC: Cardiovascular Interventions 2012; 5(9): 906-16.
[14]. Hansen KW, Sorensen R, Madsen M, Jensen JS, Mortensen PE, Lange T, Gislason GH, Galatius S. P1230
Association between early invasive management, secondary preventive medical therapy and long-term outcomes after acute coronary syndromes. European Heart Journal 2018; 39 (suppl-1): ehy565-P1230.
[15]. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European heart journal 2016; 37(3): 267-315.
[16]. Puymirat E, Aissaoui N, Cayla G, Lafont A, Riant E, Mennuni M, Saint-Jean O, Blanchard D, Jourdain P, Elbaz
M, Henry P. Changes in one-year mortality in elderly patients admitted with acute myocardial infarction in relation with early management. The American journal of medicine 2017; 130(5): 555-63.
[17]. Oh YS, Kim SH, Kim TS, Shin WS, Kim JH, Jang SW, Lee MY, Rho TH. randomized comparison of continuous and
intermittent heparin infusion during catheter ablation of atrial fibrillation. JACC: CLINICAL ELECTROPHYSIOLOGY 2016; 2 (3): 319-26.
[18]. Hamam I, Daoud EG, Zhang J, et al. Impact of international normalized ratio and activated clot- ting time on unfractionated heparin dosing during ablation of atrial fibrillation. Circ Arrhythm Elec-trophysiol 2013; 6:491-96.
[19]. Izadpanah M, Khalili H, Mohammadi M. Comparingsafety of heparin as continuous intravenous infusion andmultiple subcutaneous injections. Journal of comparative effectiveness research 2016; 5(1): 31-38.
[20]. Haines DE. Heparin Bolus or Infusion: Can We Draw aConclusion?. JACC: CLINICAL ELECTROPHYSIOLOGY2016; 2 (3): 327-29.